Search

everythinglearnresearchcommunity

for

Search:↓

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

Sorafenib can cause delayed skin problems, so patients need careful monitoring.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Gefitinib can cause rare scarring hair loss.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.

Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Tofacitinib might be used to treat hair loss.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.